- Home
- AQST vs RGNX Comparison
AQST vs RGNX Comparison
Compare AQST & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQST
- RGNX
- Stock Information
- Founded
- AQST 2004
- RGNX 2008
- Country
- AQST United States
- RGNX United States
- Employees
- AQST N/A
- RGNX N/A
- Industry
- AQST Biotechnology: Pharmaceutical Preparations
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AQST Health Care
- RGNX Health Care
- Exchange
- AQST Nasdaq
- RGNX Nasdaq
- Market Cap
- AQST 390.4M
- RGNX 451.1M
- IPO Year
- AQST 2018
- RGNX 2015
- Fundamental
- Price
- AQST $5.84
- RGNX $10.55
- Analyst Decision
- AQST Strong Buy
- RGNX Strong Buy
- Analyst Count
- AQST 7
- RGNX 8
- Target Price
- AQST $10.29
- RGNX $28.50
- AVG Volume (30 Days)
- AQST 3.6M
- RGNX 499.3K
- Earning Date
- AQST 11-03-2025
- RGNX 11-05-2025
- Dividend Yield
- AQST N/A
- RGNX N/A
- EPS Growth
- AQST N/A
- RGNX N/A
- EPS
- AQST N/A
- RGNX N/A
- Revenue
- AQST $44,132,000.00
- RGNX $155,782,000.00
- Revenue This Year
- AQST N/A
- RGNX $203.27
- Revenue Next Year
- AQST $51.50
- RGNX $0.58
- P/E Ratio
- AQST N/A
- RGNX N/A
- Revenue Growth
- AQST N/A
- RGNX 74.95
- 52 Week Low
- AQST $2.12
- RGNX $5.04
- 52 Week High
- AQST $6.43
- RGNX $12.22
- Technical
- Relative Strength Index (RSI)
- AQST 62.29
- RGNX 63.97
- Support Level
- AQST $5.47
- RGNX $9.55
- Resistance Level
- AQST $5.93
- RGNX $11.00
- Average True Range (ATR)
- AQST 0.36
- RGNX 0.50
- MACD
- AQST 0.01
- RGNX 0.11
- Stochastic Oscillator
- AQST 62.43
- RGNX 79.81
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.